BEST PRACTICE & RESEARCH: CLINICAL RHEUMATOLOGY

TABLE OF CONTENTS

- Description p.1
- Impact Factor p.2
- Abstracting and Indexing p.2
- Editorial Board p.3
- Guide for Authors p.4

DESCRIPTION

Evidence-based updates of best clinical practice across the spectrum of musculoskeletal conditions.

Best Practice & Research: Clinical Rheumatology keeps the clinician or trainee informed of the latest developments and current recommended practice in the rapidly advancing fields of musculoskeletal conditions and science.

The series provides a continuous update of current clinical practice. It is a topical serial publication that covers the spectrum of musculoskeletal conditions in a 4-year cycle. Each topic-based issue contains around 200 pages of practical, evidence-based review articles, which integrate the results from the latest original research with current clinical practice and thinking to provide a continuous update.

Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. The review articles seek to address the clinical issues of diagnosis, treatment and patient management. Management is described in practical terms so that it can be applied to the individual patient. The serial is aimed at the physician in both practice and training.

The Best Practice & Research Clinical Rheumatology series provides up-to-date and expert information and opinion by drawing on Guest Editors and authors renowned for their expertise. This ongoing review of topics makes the serial ideally suited to supporting everyday clinical practice, for training needs as well as for maintaining knowledge and competency.

Volume 22 (Volume 2008):

1. Connective tissue diseases
   M. Matucci-Cerinic & D. Furst

2. Musculoskeletal science
   T. Pap & U. Muller-Ladner

3. How to manage chronic musculoskeletal conditions - the principles
   P. Brooks & P. Conaghan
4. Miscellaneous inflammatory musculoskeletal conditions
J. Sibilia & H. Zeidler

5. Musculoskeletal conditions in the developing world
G. Mody & R. Handa

6. Imaging in musculoskeletal conditions
M. Cimmino and W. Grassi

Volume 23 (2009):
1. Early rheumatoid arthritis
2. Vasculitis
3. How to do - practical procedures
4. Back pain
5. Systemic lupus erythematosus
6. Osteoporosis

Volume 24 (2010):
1. Osteoarthritis
2. Paediatric rheumatology
3. How to manage chronic musculoskeletal conditions - a systematic approach to specific problems
4. Pharmacotherapy
5. Spondylo-arthropathies
6. Prevention / epidemiology

This free sample chapter is being provided to demonstrate the Journal's approach to topics across the spectrum of musculoskeletal conditions.

IMPACT FACTOR
2022: 5.200 © Clarivate Analytics Journal Citation Reports 2023

ABSTRACTING AND INDEXING
Scopus
PubMed/Medline
Current Contents - Life Sciences and Clinical Medicine
Science Citation Index
Web of Science
Embase
Embase
EDITORIAL BOARD

Editor in Chief
Atul Deodhar, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, L102, 97239, Portland, Oregon, United States of America

Emeritus Editor
Anthony Woolf, Royal Cornwall Hospital Rheumatology Department, TR1 3LJ, Truro, United Kingdom

Social Media Editor
Ajesh B. Maharaj, Walter Sisulu University, Mthatha, South Africa

Editorial Board
Vinod Chandran, University of Toronto, Department of Medicine, Toronto, Ontario, Canada
Cong-Qiu Chu, Oregon Health & Science University Division of Arthritis and Rheumatic Diseases, Portland, Oregon, United States of America
David I. Daikh, Portland VA Medical Center, Portland, Oregon, United States of America
M Tuncay Duruoz, Marmara University, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey
John D FitzGerald, University of California Los Angeles, Department of Medicine, Los Angeles, California, United States of America
Nigil Haroon, University of Toronto Division of Rheumatology, Toronto, Ontario, Canada
Sindhu R Johnson, University of Toronto, Institute of Health Policy, Management and Evaluation, Clinical Epidemiology & Health Care Research, Toronto, Ontario, Canada
Gurjit S. Kaeley, University of Florida College of Medicine, Division of Rheumatology, Jacksonville, Florida, United States of America
Pedro M Machado, University College London Research, Department of Neuromuscular Diseases, London, United Kingdom
Philip Mease, University of Washington School of Medicine, Seattle, Washington, United States of America
Marta Mosca, University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy
Kenneth S. O’Rourke, Rheumatology Associates, Portland, Maine, United States of America
Eduardo S. Paiva, Federal University of Parana, Department of Internal Medicine, Curitiba, Paraná, Brazil
Proton Rahman, Memorial University of Newfoundland, Faculty of Medicine, St John’s, Newfoundland and Labrador, Canada
Philip C. Robinson, The University of Queensland, Faculty of Medicine, , Australia
Chris Scott, University of Cape Town, Department of Paediatrics and Child Health, Rondebosch, South Africa
INTRODUCTION

The print edition of Best Practice & Research Clinical Rheumatology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory rheumatological practice and research.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Any conflict of interest must be disclosed at the end of your article, under a subheading "Conflict of interest statement".

Declaration of generative AI in scientific writing
The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier’s AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

Disclosure instructions
Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled 'Declaration of Generative AI and AI-assisted technologies in the writing process'.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that
its publication is approved by all authors and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in
English or in any other language, including electronically without the written consent of the copyright-
holder.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier’s sharing policy.
Sharing your preprints e.g. on a preprint server will not count as prior publication (see ‘Multiple,
redundant or concurrent publication’ for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences,
and promotes equal opportunities. Content should make no assumptions about the beliefs or
commitments of any reader; contain nothing which might imply that one individual is superior to
another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health
condition; and use inclusive language throughout. Authors should ensure that writing is free from bias,
stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek
gender neutrality by using plural nouns (“clinicians, patients/clients”) as default/wherever possible
to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer
to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health
condition unless they are relevant and valid. When coding terminology is used, we recommend
to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We
suggest using alternatives that are more appropriate and (self-) explanatory such as "primary",
"secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help
identify appropriate language but are by no means exhaustive or definitive.

Reporting sex- and gender-based analyses
Reporting guidance
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should
integrate sex and gender-based analyses (SGBA) into their research design according to funder/
sponsor requirements and best practices within a field. Authors should address the sex and/or gender
dimensions of their research in their article. In cases where they cannot, they should discuss this
as a limitation to their research's generalizability. Importantly, authors should explicitly state what
definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility
of their research and to avoid ambiguity or conflation of terms and the constructs to which they
refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research
(SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use
and editorial review of sex and gender information in study design, data analysis, outcome reporting
and research interpretation - however, please note there is no single, universally agreed-upon set of
guidelines for defining sex and gender.

Definitions
Sex generally refers to a set of biological attributes that are associated with physical and physiological
features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex
categorization (male/female) is usually designated at birth (“sex assigned at birth”), most often based
solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed
roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical
and cultural context and may vary across societies and over time. Gender influences how people view
themselves and each other, how they behave and interact and how power is distributed in society. Sex
and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging
whereas these constructs actually exist along a spectrum and include additional sex categorizations
and gender identities such as people who are intersex/have differences of sex development (DSD) or
identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important
for authors to define the manner in which they are used. In addition to this definition guidance and
the SAGER guidelines, the resources on this page offer further insight around sex and gender in
research studies.

Author contributions
For transparency, we require corresponding authors to provide co-author contributions to the
manuscript using the relevant CRediT roles. The CRediT taxonomy includes 14 different roles
describing each contributor's specific contribution to the scholarly output. The roles are:
Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology;
Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing -
original draft; and Writing - review & editing. Note that not all roles may apply to every manuscript,
and authors may have contributed through multiple roles. More details and an example.

Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and
design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the
article or revising it critically for important intellectual content, (3) final approval of the version to
be submitted.

Changes to Authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of
accepted manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove an author,
or to rearrange the author names, must be sent to the Editorial Office from the corresponding author
of the accepted manuscript and must include: (a) the reason the name should be added or removed,
or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors
that they agree with the addition, removal or rearrangement. In the case of addition or removal of
authors, this includes confirmation from the author being added or removed. Requests that are not
sent by the corresponding author will be forwarded by the Editorial Office to the corresponding author,
who must follow the procedure as described above. Note that: (1) the Editorial Office will inform the
Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue
is suspended until authorship has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange
author names in an article published in an online issue will follow the same policies as noted above
and result in a corrigendum.

Article transfer service
This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This
means that if an editor feels your manuscript is more suitable for an alternative journal, you might
be asked to consider transferring the manuscript to such a journal. The recommendation might be
provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation,
or a combination. If you agree, your manuscript will be transferred, though you will have the
opportunity to make changes to the manuscript before the submission is complete. Please note that
your manuscript will be independently reviewed by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a ‘Journal Publishing Agreement’ (for
more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will
be sent to the corresponding author confirming receipt of the manuscript together with a ‘Journal
Publishing Agreement’ form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal
circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations
(please consult https://www.elsevier.com/permissions). If excerpts from other copyrighted works are
included, the author(s) must obtain written permission from the copyright owners and credit the
source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult

Retained author rights
As an author you (or your employer or institution) retain certain rights. For more information on
author rights for:
Subscription articles please see https://www.elsevier.com/journal-authors/author-rights-and-responsibilities.
Open access articles please see https://www.elsevier.com/OAauthoragreement.

Copyright
Upon acceptance of an article, authors will be asked to complete a ‘Journal Publishing Agreement’ (see
more information on this). An e-mail will be sent to the corresponding author confirming receipt of
the manuscript together with a ‘Journal Publishing Agreement’ form or a link to the online version
of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author’s choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

*Elsevier supports responsible sharing*
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

**Open access**
Please visit our Open Access page for more information.

*Elsevier Researcher Academy*
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier’s Language Services.

**Submission and Preparation**
When you have accepted an invitation to write a review, you will receive submission and preparation instructions and deadline information from the Editorial Office.

**PREPARATION**

**Highlights**
Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Formatting of funding sources**
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Data references**

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

**Preprint references**

Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

**Reference management software**

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

**Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file’s content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply ‘stills’ with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.
AFTER ACCEPTANCE

**Online proof correction**
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Published journal**
The corresponding author, at no cost, will be provided with a copy of the journal issue in which the article is published.

**Offprints**
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**
For inquiries relating to the submission of articles, please contact the Editorial Office: berh@elsevier.com